Drug combination shows significant survival advantage in metastatic RCC

Article

The combination of bevacizumab (Avastin) and interferon-alpha (Roferon-A) as first-line treatment in patients with metastatic renal cell carcinoma offers significant improvement in progression-free survival compared with interferon-alpha alone, according to a study published in The Lancet (2007; 370:2103-11).

Related Videos
Dr. Christopher Wallis in an interview with Urology Times
Randall A. Lee, MD, answers a question during a Zoom video interview
Edward M. Schaeffer, MD, PhD, answers a Zoom video interview question
Man talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
James Ferguson III, MD, PhD, answers a question during a Zoom video interview
Nicholas L. Kavoussi, MD, answers a question during a Zoom video interview
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Related Content
© 2023 MJH Life Sciences

All rights reserved.